Dyne Therapeutics Stock Quote DYN - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

43.19

Bid

43.17

Ask

46.49

Volume

796,649

41.36 Day's Range 43.47

6.40 52 Week Range 44.33

Market Cap

3.624B

Previous Close

41.47

Open

41.63

Last Trade

42.35

Last Trade Time

Financial Volume

$ 33,662,407

VWAP

42.255

Average Volume (3m)

1,270,798

Shares Outstanding

87,382,638

Dividend Yield

PE Ratio

-16.02

Earnings Per Share (EPS)

-2.7

Revenue

Net Profit

-235.94M

Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.dyne-tx.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Dyne Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DYN. The last closing price for Dyne Therapeutics was $41.47. Over the last year, Dyne Therapeutics shares have traded in a share price range of $ 6.40 to $ 44.33.

Dyne Therapeutics currently has 87,382,638 shares outstanding. The market capitalization of Dyne Therapeutics is $3.62 billion. Dyne Therapeutics has a price to earnings ratio (PE ratio) of -16.02.

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics...

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.97	4.77923338185	41.22	44.33	40.78	953053	42.53274221	CS
4	7.9	22.3859450269	35.29	44.33	32.78	1129200	37.73795883	CS
12	18.52	75.07093636	24.67	44.33	24.67	1270798	33.04130486	CS
26	27.58	176.68161435	15.61	44.33	15.59	1320776	28.4731012	CS
52	32.33	297.697974217	10.86	44.33	6.4	1167145	22.01002859	CS
156	23.71	121.714579055	19.48	44.33	4.3	578525	18.6588313	CS
260	19.74	84.1791044776	23.45	44.33	4.3	520093	18.78291946	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	151.42M
CMAXCareMax Inc	$ 5.7101 (261.40%)	100.56M
NUKKNukkleus Inc	$ 0.5415 (69.22%)	24.87M
SNOASonoma Pharmaceuticals Inc	$ 0.423 (37.34%)	4.57M
LPSNLivePerson Inc	$ 1.2999 (31.30%)	8.57M
CGBSCrown LNG Holdings Ltd	$ 0.9902 (-29.77%)	3.29M
LGCBLinkage Global Inc	$ 3.7833 (-27.45%)	166.7k
SPECSpectaire Holdings Inc	$ 0.395 (-24.76%)	1.78M
GSUNGolden Sun Health Technology Group Ltd	$ 5.07 (-24.55%)	155.37k
SLNASelina Hospitality PLC	$ 0.0364 (-23.04%)	75.77M
NVDANVIDIA Corporation	$ 123.45 (4.68%)	221.22M
SQQQProShares UltraPro Short QQQ	$ 8.08 (-4.49%)	176.65M
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	151.42M
SERVServe Robotics Inc	$ 8.7192 (15.49%)	148.59M
NCPLNetcapital Inc	$ 0.1105 (6.25%)	121.97M